- Home
- SAVA vs ADAP Comparison
SAVA vs ADAP Comparison
Compare SAVA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- ADAP
- Stock Information
- Founded
- SAVA 1998
- ADAP 2008
- Country
- SAVA United States
- ADAP United Kingdom
- Employees
- SAVA 30
- ADAP N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- ADAP Health Care
- Exchange
- SAVA Nasdaq
- ADAP Nasdaq
- Market Cap
- SAVA 70.5M
- ADAP 71.6M
- IPO Year
- SAVA N/A
- ADAP 2015
- Fundamental
- Price
- SAVA $1.57
- ADAP $0.27
- Analyst Decision
- SAVA Buy
- ADAP Strong Buy
- Analyst Count
- SAVA 3
- ADAP 5
- Target Price
- SAVA $54.50
- ADAP $1.83
- AVG Volume (30 Days)
- SAVA 1.2M
- ADAP 2.0M
- Earning Date
- SAVA 05-09-2025
- ADAP 05-14-2025
- Dividend Yield
- SAVA N/A
- ADAP N/A
- EPS Growth
- SAVA N/A
- ADAP N/A
- EPS
- SAVA N/A
- ADAP N/A
- Revenue
- SAVA N/A
- ADAP $178,032,000.00
- Revenue This Year
- SAVA N/A
- ADAP N/A
- Revenue Next Year
- SAVA N/A
- ADAP $69.81
- P/E Ratio
- SAVA N/A
- ADAP N/A
- Revenue Growth
- SAVA N/A
- ADAP 195.34
- 52 Week Low
- SAVA $1.15
- ADAP $0.20
- 52 Week High
- SAVA $42.20
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- SAVA 45.15
- ADAP 45.56
- Support Level
- SAVA $1.37
- ADAP $0.23
- Resistance Level
- SAVA $1.73
- ADAP $0.30
- Average True Range (ATR)
- SAVA 0.13
- ADAP 0.03
- MACD
- SAVA 0.08
- ADAP 0.01
- Stochastic Oscillator
- SAVA 76.72
- ADAP 62.67
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.